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ABSTRACT  
Objectives. PCI is the gold standard for the treatment of acute myocardial infarction 
(AMI), with the main limitation of in-stent restenosis for BMS and late stent thrombosis 
(ST) for both BMS and DES. Endothelial progenitor cells (EPC) CD34+ capture stents, 
promoting vascular healing, may be advantageous in preventing ST. Aim of the study is to 
evaluate the outcomes of AMI patients treated with EPC CD34+ capture stent and 
describe the mobilization kinetics of CD34+ and their clinical correlation. 
Methods. 50 AMI patients underwent primary PCI with EPC CD34+ capture stent. Serial 
assays of CD34+ were performed by flow-cytometric analysis.  
Results. Procedural success rate was 100%. At six-months follow-up cardiac death, 
myocardial infarction, target lesion revascularization (TLR) and target vessel 
revascularization (TVR) occurred respectively in 2%, 4%, 10% and 12% of patients. No 
case of ST was observed. The MACE-free survival was 81,2%. The mean peak value of 
plasmatic CD34+ was 4,69±3,76 cells/µl. A positive correlation was found between CD34+ 
concentration, age and infarct area. No correlation was detected between CD34+ 
concentration and occurrence of TVR, TLR and MACE. 
Conclusions. EPC capture stent implantation seems to be safe and effective in the 
clinical setting of AMI, representing a possible alternative to BMS and DES. CD34+ cells 
plasmatic concentration seems not to correlate to coronary restenosis and atheromasic 
disease progression. 
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INTRODUCTION 
The gold standard for the treatment of acute myocardial infarction (AMI) is a well-timed 
mechanical revascularization in an appropriate PCI-capable center [1]. Revascularization 
procedures seem to be effective and safe both with bare-metal stents (BMS) and drug-
eluting stents (DES) [1]. The major limitations of this approach are restenosis, rising from 
5,11% with DES to 11,19% with BMS [2] and stent thrombosis (ST), rising up to 2,7% for 
both DES and BMS [2,3]. Moreover, ST results in high morbidity and mortality rates [3].  
An alternative “biological” approach could be the use of Endothelial Progenitor Cells (EPC) 
CD34+ capture stent. The physiological basis of this approach is the phenomenon of 
CD34+ spontaneous mobilization during AMI [4, 5]. Several studies demonstrated the role 
of EPC in the healing process after vascular endothelial injury [4]. The EPC CD34+ 
capture stent (Genous R stentTM, OrbusNeich, Fort Lauderdale, FL, USA) is a 
bioengineered stainless steel, dual-helix, modular stent coated with murine monoclonal 
antihuman CD34 antibodies designed to attract circulating EPC, establish a functional 
endothelial layer and therefore accelerate vascular healing. Early surface 
endothelialization could reduce the risk of ST and could positively influence restenosis 
[6,7].  Nevertheless, the functional role of EPC is still not well established [8]. In particular, 
it is not clear if EPC plasmatic concentration could influence the efficacy of this approach 
and even favor restenosis and the atheromasic disease progression [9,10]. 
The primary objective of our study was to evaluate the efficacy and safety of EPC capture 
stent in primary PCI, through the observation of clinical adverse events rate in a 
prospective cohort of ST-elevation myocardial infarction (STEMI) patients. The secondary 
aim of our study was to describe the spontaneous mobilization kinetics of CD34+ during 
Page 4 of 31 
PE
ER
 RE
VIE
W 
CO
PY
 
 
 
 
 
 
 
 
 
ED
IZI
ON
I M
INE
RV
A M
ED
ICA
Minerva Cardioangiologica
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
4 
 
AMI and to investigate the possible relationship between EPC plasmatic concentration and 
target vessel revascularization or target lesion revascularization. 
MATERIALS AND METHODS 
In a twelve-months period of time, fifty consecutive patients who underwent primary PCI 
with EPC capture stent implantation in our institution were prospectively selected and 
analyzed. Informed written consent was obtained by all patients included in the study. 
Patients were eligible for inclusion if they had STEMI within 12 hours from the beginning of 
symptoms and a culprit lesion suitable for PCI and stent implantation. Exclusion criteria 
were cardiogenic shock, pregnancy and all the physiopathological conditions determining 
poor EPC plasmatic mobilization (age > 75 years, active malignancy, hypo-regenerative 
and proliferative bone marrow diseases, active infectious diseases or sepsis, autoimmune 
diseases, previous organ transplant, active immunosuppressive therapy). No other 
predefined clinical inclusion or exclusion criteria were considered. 
The primary outcome was the occurrence of death, myocardial infarction (MI), target 
vessel revascularization (TVR), target lesion revascularization (TLR), stent thrombosis 
(ST). MACE were defined as a non-hierarchical composite of cardiac death, nonfatal MI, or 
target vessel repeat revascularization during hospital stay and at six-months follow-up. 
Secondary outcome investigated measures were EPC CD34+ plasmatic concentrations in 
the whole population and in different predefined subgroups. 
 
Definitions 
STEMI was defined as typical chest pain lasting more than 30 minutes associated with ST-
segment elevation > 1 mm in at least two contiguous leads on the ECG. [1] 
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Technical success was defined as successful deployment of stent(s) in the target lesion. 
Procedural success was defined as lesion revascularization with ≤30% residual diameter 
stenosis by quantitative coronary angiography, without major procedural or post-
procedural adverse events (death, myocardial infarction, emergency target vessel 
revascularization or acute stent thrombosis). Death was classified as either cardiac or non-
cardiac, according to the Academic Research Consortium (ARC) definition [11]. Deaths 
that could not be classified were considered cardiac. TLR was defined as any repeated 
percutaneous intervention of the target lesion or other complication of the target lesion. 
The target lesion was defined as the treated segment from 5 mm proximal to the stent to 5 
mm distal to the stent. TVR was defined as any repeated PCI of any segment on the target 
vessel, defined as the entire major coronary vessel proximal and distal to the target lesion, 
including upstream and downstream branches and the target lesion itself. Myocardial 
infarction was defined according to the ARC definitions as elevation of cardiac enzymes 
three times upper the limit of normal [11]. MACE were defined as the occurrence of 
cardiac death (CD), non-fatal myocardial infarction (MI) or TVR during the follow-up period. 
Definite, probable and possible stent thrombosis (ST) were determined according to the 
ARC definitions [11]. Definite stent thrombosis was defined as angiographic and pathologic 
confirmation of acute thrombosis in patients with acute coronary syndromes, while 
probable stent thrombosis as any unexplained death within 30 days or as target vessel MI 
without angiographic confirmation of thrombosis or other identified culprit lesion. Stent 
thrombosis was classified as acute, sub-acute, late and very late if the event occurred 
within 24 hours, 30 days, <1 year or >1 year respectively, after the procedure. 
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Procedures, medications and follow-up 
All PCIs were performed according to current guidelines. Stenting strategy, use of 
periprocedural glycoprotein IIb/IIIa inhibitors, route of arterial access, predilation devices, 
intravascular ultrasound guidance and prophylactic intra-aortic balloon pump use was at 
the discretion of the operator. All patients were pretreated with 250 mg aspirin and 300 mg 
clopidogrel loading dose; unfractioned heparin was administered in order to maintain an 
activated clotting time >250s during the procedure. After the procedure, all patients were 
prescribed lifelong aspirin 100 mg and clopidogrel 75 mg daily for 4 weeks. Patients were 
monitored for in-hospital events. Per protocol, all patients received atorvastatin 80 mg/od 
until discharge followed by drug titration in order to achieve LDL cholesterol < 80 mg/dL 
[12]. A follow-up visit was scheduled at 30 days and six months.  
All patients underwent a complete echocardiographic study at admission, at discharge and 
six months later. Echocardiographic images were obtained using an HP Sonos 5500 
scanner, equipped with a 2.5-3.75 MHz probe. Left ventricular (LV) end-systolic and end-
diastolic volumes and ejection fraction (EF) were estimated using Simpson's modified 
biplane method [13,14,15]. All echocardiographic measurements were obtained by a 
single certified experienced operator from three different cardiac cycles and were 
averaged. 
At the six-months follow-up, all patients underwent SPECT (single photon emission 
computed tomography), based on a dypiridamole stress protocol [16-19]. 
All repeat interventions and re-hospitalizations were prospectively collected during follow-
up and entered into a dedicated database. Angiographic follow-up was not scheduled per 
protocol, being performed only in case of positive stress test or recurrence of symptoms. 
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Parameters and flow-cytometric methods 
Serial assays of CD34 cell count were performed at time 0 (within the first 24 hours), 1st 
day, 2nd day, 3rd day, 5th day, 30th day. The determination of immunological markers that 
characterize endothelial precursors was assessed by flow-cytometric analysis. This 
analysis was performed on 100 µl of whole blood that was incubated 20 minutes at 4°C in 
the dark with FITC or PE antibodies. After incubation with antibodies, it was added to the 
cell suspension 1 ml of lyzing solution, held for 10 minutes at room temperature in the 
dark, in order to achieve the elimination of red blood cells that might affect the analysis. 
Then, cells were directly analyzed by flow-cytometric Facs Canto II (Becton, Dickinson). 
The flow-cytometric count was performed using ISHAGE protocol. Internal and external 
quality controls verified reliability and repeatability of tests carried out and of reagents and 
methods performances, using standard samples (internal quality control by 7-Color Setup 
beads, Becton, Dickinson, and external verification of quality UKNEQAS) [20]. 
 
Statistical analysis 
Variables with normal distribution were analyzed using parametric tests while variables 
with non-normal distribution were analyzed with non-parametric tests. Continuous 
variables are expressed as mean ± SD. Categorical variables are expressed as counts 
and percentages. All statistical tests were two-tailed. All analyses were performed using 
SPSS version 12 statistical software (SPSS Inc., Chicago, IL, USA). A p value <0.05 was 
considered statistically significant. 
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RESULTS 
Clinical and functional characteristics 
Baseline clinical characteristics are shown in Table I. 
Mean age was 62±11,5 years; 46 patients (92%) were male. Diabetes mellitus was 
present in 7 patients (14%). Hypertension was present in 34 patients (68%), 29 (58%) 
were active smokers, 11 (22%) were affected by obesity and 24 (48%) by dyslipidemia. 
Almost one-half of patients (40%) had familial history of CAD and 13 patients (26%) had 
prior personal history of CAD, 6 (12%) previous myocardial infarction, 2 (4%) previous PCI 
and 5 (10%) previous  coronary artery by-pass grafting.  
Functional characteristics are shown in table II.  
Mean ejection fraction was 47,3±8,2% at admission and 51±8,7% at discharge. The 
enzymatic mean peaks were 5,8±5,2 mg/dl for Troponin T and 185,8±146,2 mg/dl for CK-
MB. 
 
Angiographic and procedural characteristics 
Procedural characteristics are summarized in Table III. 
Mean door to balloon time was 98,9±47,7 minutes. Overall, a total of 57 lesions were 
treated and the mean stent-per-patient ratio was 1,48±0,67. Technical and procedural 
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success was achieved in all patients (100%). The most common location of AMI was the 
inferior wall, with a right coronary artery lesion in 22 cases (44%). The other lesion 
locations were: left anterior descending artery with an anterior AMI in 20 patients (40%), 
circumflex artery in 6 patients (12%) and saphenous vein graft in 2 patients (4%). Mean 
stent length was 20,4±3,22 mm (range 15-23 mm), mean stent diameter was 3,15±0,4mm 
(range 2,5-3,5mm), and mean atmosphere inflation was 15,4±1,8 atm (range 10-18 atm). 
A thrombotic lesion was found in 33 patients (66%), and in all these cases an adjunctive 
thromboaspiration treatment was performed. Downstream glycoproteins IIb/IIIa infusion 
was performed in all cases (100%). Multivessel disease with requirement of multivessel 
PCI was present in 17 cases (34%).  
 
Follow-up clinical outcomes 
Follow-up outcomes are summarized in Table IV. 
Mean in-hospital stay was 7,9±4,48 days (range 4-36). During the hospital stay, two 
patients died (4%), 1 because of refractory heart failure 10 days after the procedure and 1 
for acute stroke complications, 30 days after PCI. No majors bleedings occurred. One 
patient had stent thrombosis which occurred in a DES deployed in a non-culprit artery 
during a staged procedure. 
Follow-up (FU) was achieved in all patients (100%). At FU (mean: 168±39 days), the 
cumulative incidence of cardiac death was 2% and the incidences of MI, TLR and TVR 
were 4%, 10% and 12% respectively. A MACE occurred in 18% patients. No cases of 
subacute, late or very late stent thrombosis were detected and no patient required by-pass 
surgery. The Kaplan-Meyer analysis showed a MACE-free survival of 81,2%  (Figure 1). 
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Due to the small sample population, no independent predictors of adverse events were 
identified at the multivariate analysis.  
 
Mobilization kinetics of EPC CD34+ 
The analysis of biokinetics showed a mean EPC CD34+ plasmatic peak value of 
4,69±3,76 cells/μl (range 1,44 – 19,09) and an overall mean concentration of 2,66±2,4 
cells/μl. Similar mean EPC CD34+ plasmatic levels were detected respectively at time 0 
(2.9±3.0 cells/μl, range 0,68 – 7,65),  24 hours (2.4±2.2 cells/μl, range 0,65 – 12,2),  48 
hours (3.2±2.5 cells/μl, range 0,61 – 13,9), 72 hours (2.3±1.4 cells/μl, range 0,66 – 6,18),  
5 days (3.0±1.9 cells/μl, range 0,64 – 10,6) and 1 month (2.7±3.3 cells/μl, range 0,58 – 
19,09). No significant differences were demonstrated between the mean EPC  CD34+ 
plasmatic concentrations at the different assays (Figure 2).  
EPC CD34+ plasmatic mobilization kinetics in different clinical subgroups are summarized 
in table V. Significantly higher mean peak EPC CD34+ plasmatic levels were found in 
patients younger than 60 years (5,96±4,88 vs 3,61±2,14 cells/μl, p<0.05) and in subjects 
with IVA-related AMI (5,80±5,43 vs 3,89±1,68 cells/μl, p<0,05).  
EPC mobilization was higher in non diabetic patients (4,87±4,05 vs 3,62±1,47 cells/μl), in 
subjects with low EF at presentation (4,82±4,31 vs 4,5±2,48 cells/μl) and in patients 
showing less than 3 cardiovascular risk factors (5,15±4,05 vs 4,32±3,62 cells/μl), but the 
differences were not statistically significant. 
Furthermore, no significant differences were found in EPC plasmatic levels between 
patients presenting or not MACE (4,19±1,81vs 4,81±4,13 cells/μl), TVR (4,46±2,09 vs 
4,72±4,01 cells/μl) and TLR (4,22±2,24 vs 4,74±3,96 cells/μl). 
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DISCUSSION  
The main findings of this report are the following: 1) EPC capture stent use in primary 
intervention resulted in satisfactory clinical outcomes; 2) despite the short period of DAT 
and the high thrombophilic status of the patients in the acute and sub-acute phase, no 
sub-acute, late or very late stent thrombosis occurred; 3) no relationship was found 
between EPC plasmatic concentration and coronary restenosis or atheromasic disease 
progression. 
The gold standard for the management of acute myocardial infarction is mechanical 
revascularization using either BMS or DES [1]. The main limitation for the use of either 
BMS or DES is an increased risk for stent thrombosis, with consequent high morbidity and 
mortality rates [3] 
. Moreover, BMS efficacy is limited by the restenosis rate [2].  Data from literature report a 
reduced TVR rate for patients treated with DES instead of BMS (5,11% versus 11,19% 
respectively, p < 0,001); the recurrent infarction rate is as well lower (3,02% versus 3,70% 
respectively, p = 0,02), but no significant difference is described in terms of cardiac death 
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(2,80% versus 3,52% respectively, p = 0,21) and stent thrombosis (2,65% versus 2,76% 
respectively, p = 0,37) [2].  
In the clinical setting of AMI, EPC mobilization from the bone marrow is stimulated and the 
use of EPC CD34+ capture stents, accelerating the natural healing process [20,6] could be 
advantageous.  
Although not having data concerning the efficacy profile of those devices at very long term, 
data from the HEALING II study showed low MACE and low stent thrombosis rate in stable 
patients undergoing elective PCI [6]. EPC capture stent implantation has moreover shown 
to be safe in a general population of patients with acute myocardial infarction [22] as well 
as in series of high cardiovascular risk patients [23]. Furthermore, in small series of 
patients with contraindication to prolonged DAT, those devices have proven an excellent 
efficacy and safety profile [24,25].  
Recent studies representing larger populations of patients with STEMI treated with EPC 
capture stents confirm the long term safety and efficacy of those devices, showing low 
rates of MACE of 8,1% at 30 days, 10,0% at six months and 12,2% at 1 year [26]. If 
compared to DES, EPC capture stents did not show a statistically significant difference in 
terms of MACE, TVR and repeated non-fatal AMI [27]. Our results in terms of MACE 
(18%) and CD (2%) are consistent with those described in series of AMI patients [26,27] 
and high risk not selected patients [28]. 
Despite the short period of DAT and the high trombophylic status of the patients in the 
acute and sub-acute phase, no sub-acute, late or very late stent thrombosis occurred in 
our population. The only thrombotic event was observed in a DES deployed in a non-
culprit artery during a staged procedure. Data from other studies using EPC CD34+ 
capture stent in primary intervention report a stent thrombosis rate between 0,9% and 
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1,05% [26,27]. The ST rate with either BMS and DES rises from 2,65% to 2,76% [2]. 
Although considering the limitation of a small sample population in detecting thrombotic 
events, our findings add evidence to the efficacy of EPC capture stents in terms of stent 
thrombosis prevention. 
There is still no consensus in literature about the role of EPC in the atherogenic process 
and mainly in the occurrence of in-stent restenosis after successful percutaneous 
revascularization. Patients who experience in-stent restenosis seem to have higher 
plasmatic levels of each EPC sub-population if compared to those without significant 
progression of coronary atherosclerosis and to normal controls [9, 29]. This finding 
suggests a possible role of those cells in the progression of coronary atherosclerosis, 
probably through an abnormal engrafting and an excessive intimal proliferation [30]. Some  
reports are in contrast, observing that decreased in-stent late lumen loss was associated 
with higher levels of circulating EPC [31,32,33]. In our population no correlation was found 
between EPC plasmatic concentration and adverse clinical outcomes, with particular 
reference to TVR and TLR. The cell mobilization after AMI seems to be more influenced by 
general characteristics (such as the age) and baseline pathologic conditions (type of AMI).  
These discrepancies between different reports may be explained by the differences in 
study design and analyzed cell populations [30]. It is therefore possible that the EPC sub-
population may be composed of various types of different precursor, each one with a 
different and not yet understood role in atherogenesis.  
 
Limitations 
The present study was designed as a prospective single centre registry, and therefore 
lacks randomization and intention-to-treat data. Sample size was relatively small and 
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events adjudication  was not blinded. However, given the lack of large studies on EPC 
capture stent implantation in AMI and particularly of any study reporting correlations 
between EPC mobilization and the clinical outcome, this study, despite its inherent 
limitations in internal and external validities, could add an useful piece of information about 
the use of this novel device. 
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TABLE AND FIGURE LEGENDS: 
Table 1. Baseline clinical characteristics. 
IDDM: insulin dependent diabetes mellitus; NIDDM: non insulin dependent diabetes 
mellitus; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; 
AMI: acute myocardial infarction 
Table 2. Functional characteristics. 
Table 3. Angiographic and procedural characteristics. 
LAD: left anterior descending artery; Cx: circumflex artery; RCA: right coronary artery; 
SVG: saphenous vein graft; PCI: percutaneous coronary intervention  
Table 4. Cumulative incidence of adverse events. 
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MI: myocardial infarction; PCI: percutaneous coronary intervention; MACE: major adverse 
cardiovascular events; ST: stent thrombosis; TLR: target lesion revascularization; TVR: 
target vessel revascularization. 
*ST occurred in a DES deployed in a non infarction-related artery during a staged 
procedure; MI: myocardial infarction; PCI: percutaneous coronary intervention; MACE: 
major adverse cardiac events; ST: stent thrombosis; FU: follow-up; TLR: target lesion 
revascularization; TVR: target vessel revascularization. 
Table 5. Plasmatic mobilization kinetics of EPCs in different clinical subgroups. 
EPC: endothelial progenitor cells; AMI: acute myocardial infarction; EF: ejection fraction. 
 
Figure 1. MACE free survival rate. 
 
Figure 2. Box and Whisker plot of EPC mobilization. 
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Table I. Baseline clinical characteristics 
 
 N, mean±SD % 
Age (years) 62±11,5  
Gender (male) 46 92 
Hypertension 34 68 
Dyslipidemia 24 48 
Diabetes 7 14 
IDDM 2 4 
NIDDM 5 10 
Active smokers 29 58 
Obesity 11 22 
Familiar history 20 40 
Previous PCI 2 4 
Previous CABG 5 10 
Previous AMI 6 12 
 
IDDM: insulin dependent diabetes mellitus; NIDDM: non insulin dependent diabetes 
mellitus; PCI: percutaneous coronary intervention; CABG: coronary artery bypass graft; 
AMI: acute myocardial infarction 
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 Table II. Functional characteristics. 
 N, mean±SD 
Ejection fraction at admission (%) 47,3±8,2 
Ejection fraction at discharge (%) 51±8,7 
Troponin T peak (mg/dL) 5,8±5,2 
CK-MB peak (mg/dL) 185,8±146,2 
 
Table III. Angiographic and procedural characteristics. 
LAD: left anterior descending artery; Cx: circumflex artery; RCA: right coronary artery; 
SVG: saphenous vein graft; PCI: percutaneous coronary intervention  
 
 N, mean±SD % 
Technical success 50 100 
Procedural success 50 100 
Door to balloon time (min) 98,9±47,7  
Infarct Related Artery   
LAD 20 40 
Cx 6 12 
RCA 22 44 
SVG 2 4 
Evidence of thrombus 33 66 
GP IIb/IIIa use 50 100 
Multivessel PCI 17 34 
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67 
68 
69 
70 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
Stents/patient (mean) 1,48±0,67  
Treated lesion/patient (mean) 1,14±0,4  
Stent Length (mm) 20,4±3,22  
Stent diameter (mm) 3,15±0,4  
Pressure (atm) 15,4±1,8  
 
 
 
 
 
 
 
 
 
 
 
 
Table IV. Cumulative incidence of adverse events. 
 
 N % 
In-hospital stay (days) 7,9±4,48  
In-hospital events   
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31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
81 
82 
83 
84 
85 
86 
87 
88 
89 
90 
91 
92 
93 
94 
95 
Death 2 4 
Cardiac Death 1 2 
Non Cardiac Death 1 2 
Re-MI 0 0 
Re-PCI 1 2 
Major bleedings 0 0 
Minor bleedings 0 0 
Stroke 1 2 
MACE (hierarchical) 1 2 
Definite/probable ST 1* 2 
Events at FU (168±46 days)   
Death 2 4 
Cardiac D 1 2 
Non cardiac D 1 2 
MI 2 4 
TLR 5 10 
TVR 6 12 
Major bleedings 0 0 
Minor bleedings 0 0 
Stroke 1 2 
MACE (hierarchical) 9 18 
Definite/probable ST 1* 2 
 
*ST occurred in a DES deployed in a non IRA during a staged procedure MI: myocardial 
infarction; PCI: percutaneous coronary intervention; MACE: major adverse cardiac events; 
ST: stent thrombosis; FU: follow-up; TLR: target lesion revascularization; TVR: target 
vessel revascularization. 
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Table V. Plasmatic mobilization kinetics of EPCs in different clinical subgroups. 
 
 Mean EPC concentration (cells/μl) P-value 
Age                      < 60 years 
                            ≥ 60 years 
5,96±4,88 
3,61±2,14 
< 0,05 
Risk factors                      ≥3 
                                         <3 
4,32±3,62 
5,15±4,05 
NS 
Diabetes                         yes 
                                        no 
3,62±1,47 
4,87±4,05 
NS 
IMA                         anterior 
                        non-anterior 
5,80±5,43 
3,89±1,68 
< 0,05 
EF at admission          ≥50% 
                                    <50% 
4,5±2,48 
4,82±4,31 
NS 
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